CA SB1430

Authorizes the California Department of Health Care Services to enter into value-based arrangements with drug manufacturers based on outcome data or other metrics for Medi-Cal drugs.

Permits value-based arrangements to include rebates, discounts, price reductions, risk sharing, shared savings payments, bonuses, and patient care contributions.

Maintains existing requirements that the department contract with manufacturers of single-source drugs on a negotiated basis and multisource drugs on a bid or negotiated basis.

Clarifies that the department is the purchaser of prescribed drugs under Medi-Cal to obtain favorable prices and discounts based on large purchase quantities, within federal law limits.